IPR2018-00125 Patent Owner's Preliminary Response

Filed on behalf of Patent Owner Gilead Pharmasset LLC by:

David L. Cavanaugh (Reg. No. 36,476) Emily R. Whelan (Reg. No. 50,391) Samantak Ghosh (Reg. No. L1032) E. Ross Cohen (Reg. No. 72,115) WILMER CUTLER PICKERING HALE AND DORR LLP 1875 Pennsylvania Ave., NW Washington, DC 20006 Dorothy P. Whelan (Reg. No. 33,814) Michael J. Kane (Reg. No. 39,722) W. Chad Shear (Reg. No. 47,938) FISH & RICHARDSON P.C. 60 South Sixth Street, Suite 3200 Minneapolis, MN 55402

UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC.
Petitioner,
v.
GILEAD PHARMASSET LLC,
Patent Owner.
Case IPR2018-00125
Patent 8,633,309

PATENT OWNER'S PRELIMINARY RESPONSE



TABLE OF CONTENTS

		Page
I. IN	TRODUCTION	1
II. TI	ECHNOLOGY BACKGROUND	3
A.	Sofosbuvir Revolutionized the Standard of Care for Hepatitis C Virus Infection	3
B.	Nucleosides and Nucleotides	5
C.	Stereoisomers and Diastereomers	6
D.	Sofosbuvir Is a Nucleoside Phosphoramidate Prodrug	8
III. TI	HE CLAIMED INVENTION	10
A.	Overview of the '309 Patent	10
B.	Prosecution History	12
IV. PI	ERSON OF ORDINARY SKILL IN THE ART	15
V. CI	LAIM CONSTRUCTION	15
VI. PI	ETITIONER'S ASSERTED PRIOR ART REFERENCES	17
A.	Sofia '634	17
B.	Congiatu	18
C.	Clark '147	20
	ROUND ONE – CLAIMS 1-12 ARE NOT ANTICIPATED BY OFIA '634 Error! Bookmark not de	fined.
A.	Petitioner's Anticipation Theory Fails Because It Has Not Shown That Sofia '634 Expressly or Inherently Teaches the Purity Limitations Required by Each of the '309 Patent Claims	21
В.	Petitioner Cannot Ignore the Purity Limitations	24



	ROUND TWO – CLAIMS 1-12 ARE NOT OBVIOUS IN VIEW F SOFIA '634 AND CONGIATU	28
A.	Petitioner's Obviousness Theory Fails Because It Has Not Established That Sofia '634 and Congiatu Teach or Suggest Every Element of the '309 Patent Claims	28
В.	Petitioner Has Failed to Establish a POSA's Motivation to Combine Sofia '634 with Congiatu, or That a POSA Would Have Had a Reasonable Expectation of Success in Doing So	32
C.	Petitioner's Prosecution History Arguments Amount to Nothing More Than a Conclusory Disagreement with the Examiner	35
	ROUND THREE – CLAIMS 1-12 ARE NOT OBVIOUS IN VIEW F CLARK '147 AND CONGIATU	37
A.	Neither Clark '147 nor Congiatu Teaches or Suggests the Compounds Recited in the '309 Patent Claims	38
В.	Neither Clark '147 nor Congiatu Teaches or Suggests the Purity Limitations	40
C.	Petitioner Has Failed to Establish a POSA's Motivation to Combine Clark '147 with Congiatu, or That a POSA Would Have Had a Reasonable Expectation of Success in Doing So	43
D.	Petitioner's Prosecution History Arguments Amount to Nothing More Than a Conclusory Disagreement with the Examiner	45
X. TH	IE PETITION SHOULD BE DENIED UNDER § 325(d)	47
XI. PR	ESERVATION OF RIGHTS UNDER OIL STATES	51
VII CC	MCLUCION	<i>5</i> 1




TABLE OF AUTHORITIES

	Page(s)
Federal Cases	
Akzo N.V. v. U.S. International Trade Commission, 808 F.2d 1471 (Fed. Cir. 1986)	30
In re Anthony, 414 F.2d 1383 (C.C.P.A. 1969)	26
Apotex Inc. v. OSI Pharmaceuticals, Inc., No. IPR2016-01284, Paper 8 (P.T.A.B. Jan. 9, 2017)	48
In re Baird, 16 F.3d 380 (Fed. Cir. 1994)	39
Bettcher Industries v. Bunzl USA, Inc., 661 F.3d 629 (Fed. Cir. 2011)	22, 23
Bicon, Inc. v. Straumann Co., 441 F.3d 945 (Fed. Cir. 2006)	16
CFMT, Inc. v. YieldUp International Corp., 349 F.3d 1333 (Fed. Cir. 2003)	28
Coalition for Affordable Drugs VII LLC v. Pozen Inc., No. IPR2015-01344, 2015 Pat. App. LEXIS 12669 (P.T.A.B. Dec. 17, 2015)	23, 25
Cuozzo Speed Technologies, LLC v. Lee, 136 S.Ct. 2131 (2016)	15
Daiichi Sankyo Co. v. Matrix Laboratories, Ltd., 619 F.3d 1346 (Fed. Cir. 2010)	39
Eli Lilly & Co. v. Board of Regents of University of Washington, 334 F.3d 1264 (Fed. Cir. 2003)	39
Forest Laboratories, Inc. v. Ivax Pharmaceuticals, Inc., 501 F 3d 1263 (Fed. Cir. 2007)	27



Hospira, Inc. v. Genentech, Inc., No. IPR2017-00739, 2017 Pat. App. LEXIS 10044 (P.T.A.B. July 27, 2017)	50
Innogenetics, N.V. v. Abbott Laboratories, 512 F.3d 1363 (Fed. Cir. 2008)	4
Insite Vision Inc. v. Sandoz, Inc., 783 F.3d 853 (Fed. Cir. 2015)	32
Intelligent Bio-Systems, Inc. v. Illumina Cambridge, Ltd., 821 F.3d 1359 (Fed. Cir. 2016)34, 4	ŀ5
InTouch Technologies, Inc. v. VGO Communications, Inc., 751 F.3d 1327 (Fed. Cir. 2014)	ļ4
King Pharmaceuticals, Inc. v Eon Labs, Inc., 616 F.3d 1267 (Fed Cir. 2010)21, 2	22
<i>In re Kotzab</i> , 217 F.3d 1365 (Fed. Cir. 2000)32, 3	3
KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007)30, 4	12
Lantech, Inc. v. Keip Machine Co., 32 F.3d 542 (Fed. Cir. 1994)2	27
Medichem, S.A. v. Rolabo, S.L., 437 F.3d 1157 (Fed. Cir. 2006)	81
In re Miller, 441 F.2d 689 (C.C.P.A. 1971)2	25
Neil Ziegman, N.P.Z., Inc. v. Stephens, No. IPR2015-01860, 2016 Pat. App. LEXIS 1127 (P.T.A.B. Feb. 24, 2016)4	19
Prism Pharma Co. v. Choongwae Pharma Corp., No. IPR2014-00315, 2014 Pat. App. LEXIS 4429 (P.T.A.B. July 8, 2014)	18



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

